CIBC Private Wealth Group
AUPH icon

CIBC Private Wealth Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

CIBC Private Wealth Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$16 Buy
+1
New +$14 ﹤0.01% 3372

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CIBC Private Wealth Group's AUPH Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Aurinia Pharmaceuticals (AUPH) in Q4 2025: 1 share worth $16. The stake represents ﹤0.01% of the portfolio and ranks #3372 among its holdings.

255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

  • CIBC Private Wealth Group held 1 share of Aurinia Pharmaceuticals worth $16 as of Q4 2025.
  • Aurinia Pharmaceuticals was a new CIBC Private Wealth Group position in Q4 2025.
  • Aurinia Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #3372 holding.
  • 255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.